FDA rubber-stamps Remdesivir for infants without evidence of safety, efficacy

“75% of infants had adverse reactions

“I don’t believe every pediatrician will accept the FDA’s guidance so readily.

It’s not easy to place an intravenous line to administer remdesivir in the tiny vein of an irritable baby coming from home with a positive rapid test. And then do it again the next day. And the day after that.

At some point, clinicians’ sensibilities will be challenged enough to compel them to actually examine how the FDA arrived at its conclusions. ” Madhava Setty, M.D.